ISRCTN56498577
Completed
未知
Early External Cephalic Version (ECV) 2 trial
McMaster University Medical Centre (Canada)0 sites1,460 target enrollmentApril 22, 2005
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Pregnancies with a foetus in breech presentation
- Sponsor
- McMaster University Medical Centre (Canada)
- Enrollment
- 1460
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Women with any breech presentation, aged 18 \- 49 years old
- •2\. A live singleton foetus
- •3\. Gestational age of 33^0/7 \- 35^6/7 weeks
Exclusion Criteria
- •1\. Any contraindication to ECV
- •2\. Previous participation in the EECV2 Trial
- •3\. Any contraindication to early ECV
- •4\. Women who wish a vaginal delivery if the foetus remains breech
- •5\. Any contraindication to labour or vaginal birth
- •6\. Women who wish to deliver by Caesarean Section (CS) if the foetus turns to cephalic
- •7\. Women at increased risk of unstable lie
- •Please note that the following exclusion criteria was removed from this list on 06/11/2007:
- •8\. Women who plan to move to a non\-trial centre prior to delivery
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczemaChronic hand eczemaMedDRA version: 20.0Level: LLTClassification code 10066695Term: Chronic hand dermatitisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: SOCClassification code 10040785Term: Skin and subcutaneous tissue disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-000900-40-DKEO Pharma A/S250
Active, not recruiting
Phase 1
First-in-Human Study of IMGC936 in Patients With Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-002264-41-ESImmunoGen, Inc.250
Active, not recruiting
Phase 1
Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10036921 Term: Prostate carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10030052 Term: Ocular melanomas System Organ Class: 100000004853MedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003555-38-ESMacroGenics, Inc.193
Active, not recruiting
Phase 1
Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003555-38-PLMacroGenics, Inc.182
Recruiting
Phase 1
First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancernresectable Locally Advanced or Metastatic CancerMedDRA version: 21.0Level: PTClassification code: 10061289Term: Metastatic neoplasm Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-504012-16-00Takeda Development Center Americas Inc.129